Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

PET/CT Imaging of Human TNFa Using [89Zr]Certolizumab Pegol in a Transgenic Preclinical Model of Rheumatoid Arthritis. Molecular imaging and biology Beckford-Vera, D. R., Gonzalez-Junca, A., Janneck, J. S., Huynh, T. L., Blecha, J. E., Seo, Y., Li, X., VanBrocklin, H. F., Franc, B. L. 2019

Abstract

Tumor necrosis factor alpha (TNFa) drives inflammation and bone degradation in patients with rheumatoid arthritis (RA). Some RA patients experience a rapid clinical response to TNFa inhibitors such as certolizumab pegol (CZP) while other patients show limited to no response. Current methods for imaging RA have limited sensitivity and do not assist in the selection of patients most likely to respond to immune-mediated therapy. Herein, we developed a novel positron emission tomography (PET) radiotracer for immuno-PET imaging of TNFa in transgenic human TNFa-expressing mice.CZP was modified with p-isothiocyanatobenzyl-deferoxamine (DFO) and radiolabeled with Zr-89. The biological activity of [89Zr]DFO-CZP was evaluated by HPLC and binding assay using human recombinant TNFa (hTNFa). The feasibility of specific immuno-PET imaging of human TNFa was assessed in a transgenic mouse model of RA that expresses human TNFa. This model resembles the progression of RA in humans by maintaining lower levels of circulating hTNFa and exhibits chronic arthritis in the forepaw and hind paw joints. The dosimetry of [89Zr]DFO-CZP in humans was estimated using microPET/CT imaging in Sprague Dawley rats.[89Zr]DFO-CZP was isolated with radiolabeling yields of 85?±?6 % (n?=?5) and specific activities ranging from 74 to 185 MBq/mg (n?=?5). Following size exclusion purification, the radiochemical purity of [89Zr]DFO-CZP was greater than 97 %. [89Zr]DFO-CZP retained high immunoreactivity with more than 95 % of the radioactivity shifted into higher molecular weight complexes. Images showed increasing uptake of the tracer in forepaw and hind paw joints with disease progression. No uptake was observed in the model previously administered with an excess amount of unmodified CZP and in normal control mice, demonstrating in vivo specific uptake of [89Zr]DFO-CZP.The feasibility of immuno-PET imaging of human TNFa with [89Zr]DFO-CZP has been demonstrated in a preclinical model of RA.

View details for DOI 10.1007/s11307-019-01363-0

View details for PubMedID 31065895